Clinical effect comparison of the treatment for locally advanced nasopharyngeal carcinoma by different chemotherapy regimen combined radiotherapy: a randomised controlled study

Clinical effect comparison of the treatment for locally advanced nasopharyngeal carcinoma by different chemotherapy regimen combined radiotherapy: a randomrized controlled study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002421

Enrollment

Unknown

Registered

2012-08-13

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

control group:fluorouracil+cisplatin chemotherapy plus radiotherapy

intervention group :gemcitabine+cisplatin chemotherapy plus radiotherapy

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age from18 to 60 years; No contraindication to chemotherapy; Pathological classification: World Health Organization (WHO) type II or III disease; The clinical stages only consisting of III, IVa stage (7th edition AJCC classification of nasopharyngeal carcinoma); All cases not received the chemotherapy, radiation therapy, surgical treatment before randomization, Karnofsky performance score (KPS) >=80 points. Normal renal function: creatinine clearance rate >=60 ml/min; normal blood routine test: white blood cells >=4000/ul, platelets>=100000/ul.

Exclusion criteria

Exclusion criteria: Pathological type is adenocarcinoma. Ages>60 or <18 years; karnofsky performance scores <80; first diagnosed NPC with distant metastasis; patients with not-tumor associated death; patients with heart lung liver renal insufficiency; recurrence patients. Surgical history of primary lesion and metastasis .Once received radiotherapy or chemotherapy.

Design outcomes

Primary

Measure	Time frame
relapse free survival;	—

Secondary

Measure	Time frame
overall survival;acute toxicity;	—

Countries

China

Contacts

Public ContactWei Jiang

weijiang@glmc.edu.cn+86 13533703015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026